Intrathecal Rituximab as a Rescue Therapy in Refractory Pure CSF Positive, Non-Teratomatous Type Anti-NMDAR Encephalitis

Parameswaran Krishnan, Kurian Thomas
Department of Neurology, Indo American Hospital Institute of Brain and Spine, Vaikom, Kerala, India

Abstract

NMDAR antibody encephalitis is the most common autoimmune encephalitis characterized by a myriad of neuropsychiatric symptoms. It predominantly affects females and is associated with ovarian teratoma (58%). Nineteen percent do not respond to treatment and are left with serious neurological deficits. A subset of NMDAR encephalitis with antibody positivity in CSF alone without ovarian teratoma is often found to be refractory to treatment. We name them Pure CSF positive, non-teratomatous type anti-NMDAR encephalitis. We report two such cases who responded to intrathecal rituximab, to highlight a novel treatment as a rescue therapy to prevent long-term disability and improve clinical outcomes.

Keywords: Anti NMDA receptor encephalitis, intrathecal injection, non-paraneoplastic anti-NMDAR encephalitis, rituximab

Introduction

Autoimmune encephalitis (AE) is a debilitating neurological disorder that causes a range of neurological and psychiatric symptoms.[1] N-methyl-D-aspartate receptor antibody encephalitis (NMDARE), the most common form of AE, is characterized by abnormal behavior, cognitive dysfunction, seizures, movement disorders, reduced consciousness, mutism, autonomic dysfunction, hypoventilation, and memory deficits.[1-5] Clinical presentation is determined by the degree of active CNS inflammation, and therefore, the mainstay of treatment is immunosuppression. Early commencement of immunotherapy may prevent major disability.[2,6,7]

We report two cases of severe NMDARE refractory to treatment that responded to rescue therapy with low-dose intrathecal rituximab. Rituximab is a chimeric monoclonal antibody against CD20-positive B lymphocytes (B cells) inducing B-cell depletion.[2,6]

Case History

Case no 1

A 15-year-old girl presented with sub-acute encephalopathy, severe orofacial dyskinesias, new onset status epilepticus, psychosis, and severe autonomic dysfunction. She later became mute and non-communicative. Her clinical presentation was classical of NMDARE, but serum autoimmune panel was negative. CSF showed markedly elevated titer of NMDAR antibody. Serial search for ovarian teratoma with ultrasound, CT, and MRI pelvis turned up negative. MRI brain was normal. EEG showed diffuse generalized slowing. She was initiated on first-line immunotherapy with intravenous methylprednisolone and intravenous immunoglobulin (IVIg). Despite treatment initiation, she continued to deteriorate, and hence, 5 cycles of plasma exchange (PLEX) were given. Her condition further deteriorated with severe respiratory disturbance and status epilepticus requiring mechanical ventilation. Even after 2 months of second-line therapy with intravenous rituximab, she continued to be mute, non-communicative, and bedbound with recurrent seizures. Although we were not able to demonstrate ovarian teratoma, exploratory laparotomy was performed and suspicious cysts were removed. Histopathological examination was normal. We then administered IV cyclophosphamide, but she continued to deteriorate. After getting informed consent, we gave 25 mg intrathecal rituximab weekly for 4 weeks. Second day after intrathecal rituximab patient started improving with increased responsiveness and seizure control. She became normal by 3-4 weeks. She continues to be in clinical remission after 8 months of administration of intrathecal rituximab.

Case no 2

A 16-year-old student presented with sub-acute onset encephalopathy with severe psychosis and recurrent orofacial

Address for correspondence: Dr. Kurian Thomas, Consultant Neurologist, Department of Neurology, Indo American Hospital Institute of Brain and Spine, Chemmanakary, Vaikom, Kottayam - 686 143, Kerala, India. E-mail: kurianhere@gmail.com

Submitted: 09-Feb-2022 Revised: 24-Mar-2022 Accepted: 31-Mar-2022 Published: 13-May-2022

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKLHRPMedknow_reprints@wolterskluwer.com

DOI: 10.4103/ain.ain_134_22
brachial dyskinetic seizures. Her serum NMDA antibody was negative; however, her CSF NMDA antibody was strongly positive. Workup for teratoma was negative. Her MRI brain and CSF parameters were normal. She was treated initially with IV methylprednisolone and IVIG followed by PLEX. Subsequently, we treated her with two doses of intravenous rituximab followed by cyclophosphamide. As there was no response, we then treated her with 25 mg rituximab intrathecally for 4 weeks after getting informed consent. She showed rapid improvement with more alertness and started vocalizing 2–3 days after first dose of intra-thecal rituximab. She recovered fully and continues to remain so at the end of 8 months.

**DISCUSSION**

Anti-NMDARE is the most common non-infectious autoimmune limbic encephalitis. The disease mainly affects young females (median 21 years, range 1–85 years). Fifty-eight percent of cases are associated with ovarian teratoma. Teratomas contain neuronal cells that induce immunologic sensitization against NMDA receptors. These antibodies reach CNS, cause crosslinking, internalization, and reversible reduction in the number of NMDA receptors leading to the clinical picture of anti-NMDA receptor encephalitis. Diagnosis of NMDAR encephalitis is confirmed by detection of IgG antibodies to the GluN1 subunit of NMDA receptor in CSF, while serum testing is less reliable.

Clinical therapy includes first-line immunotherapy (corticosteroids, IVIg, and PLEX), second-line immunotherapy (intravenous rituximab, cyclophosphamide, azathioprine, and mycophenolate mofetil), and tumor removal. The use of second-line immunotherapies in AE due to autoantibodies against cell surface antigens is associated with a better outcome and lower rates of relapse. The death rate in anti-NMDARE ranges from 2% to 5%. With early appropriate therapy, 81% patients show good recovery. Plasma cells secreting high amount of NMDAR antibodies found in perivascular, interstitial, and Virchow Robin spaces of brain are responsible for intrathecal synthesis of antibodies in anti-NMDAR encephalitis. Hence, the ideal therapy should eliminate the intrathecal antibody. Preserved integrity of blood brain barrier (BBB) in anti-NMDARE along with limited penetration of IVIG, steroids, rituximab, and cyclophosphamide may be responsible for the restricted response to immunotherapy seen in patients with high levels of synthesized antibodies in CSF.

Anti-NMDARE in children is less associated with teratomas, and failure of first-line therapies is more frequent among children without tumor. This non-teratomatous, non-paraneoplastic type, pure CSF positive anti-NMDARE seems to be a separate entity often refractory to treatment. Intrathecal methotrexate and dexamethasone have been successfully tried in refractory cases of anti-NMDARE. Intravenous rituximab has only 1% penetration into CSF and may be less effective against the long living intracranial memory B cells. Casares et al. administered intrathecal rituximab in a patient with CSF NMDA antibody positivity with good clinical improvement and reduction in antibody titers.

Antibody titer changes in CSF rather than in serum are more closely related to clinical outcome in patients with anti-NMDARE. In the absence of prospective and randomized data, therapeutic strategies in anti-NMDARE are based on observational studies and clinical experiences. We report 2 children who had anti-NMDAR antibodies present only in CSF and no associated ovarian teratoma. Both patients were refractory to first- and second-line immunotherapy, and we tried intra-thecal rescue therapy with rituximab after ethical committee clearance. We postulate that intrathecal rituximab has a direct impact on inflammatory environment and suppresses the intrathecal synthesis of antibodies resulting in rapid clinical improvement and sustained clinical response. This can be considered as a rescue therapy in refractory cases. Long-term follow-up is essential as a relapse in NMDAR encephalitis is seen in up to 25% cases and may even occur after several years. We plan to closely follow up our patients clinically and ascertain the need for future treatment.

We have not ascertained serial quantitative titers of NMDA in our patients. Quantitative NMDA titers pre- and post-intrathecal rituximab administration (which have been documented in other studies) may further help in validating this novel approach.

Advantages of intrathecal rituximab include low dosage, cost effectiveness, rapid onset of action, negligible side effects, and sustained response. The use of intrathecal rituximab are mild and dose related. These include nausea, vertigo, paresthesia, and refractory hypertension. However, low dosage—25 mg as a 1:1 dilution is safe and can avoid hypertension which may be encountered at higher dosages.

Pure CSF positive non-teratomatous, non-paraneoplastic type of anti-NMDARE is a subset of autoimmune encephalitis seen more commonly in young girls, often refractory to conventional therapy. Low-dose intrathecal rituximab (25 mg x 4 doses) seems to be safe with good clinical outcome and can be considered a rescue therapy in those refractory to conventional therapy.

**Key messages**

Pure CSF positive – non-teratomatous type anti-NMDAR encephalitis is often treatment refractory and low-dose intrathecal rituximab provides a safe, effective treatment option with rapid and sustained clinical response.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other
clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-8.

2. Titulaer M, McCracken L, Gabilondo I, Arangüe T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurology 2013;12:157-62.

3. Dalmau J, Tüzün E, Wu H, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti–N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25-36.

4. Wright S, Hacohen Y, Jacobson L, Agrawal S, Gupta R, Philip S, et al. N-methyl-D-aspartate receptor antibody-mediated neurological disease: Results of a UK-based surveillance study in children. Arch Disease Child 2015;100:521-6.

5. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody encephalitis: Temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010;133:1655-67.

6. Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014;83:142-50.

7. Nosadini M, Mohammad SS, Ramanathan S, Brilot F, Dale RC. Immune therapy in autoimmune encephalitis: A systematic review. Expert Rev Neurother 2015;15:1391-419.

8. Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med 2018;378:840-51.

9. Dalmau J, Arangüe T, Planagumá J, Radosevic M, Mannara F, Leypoldt F, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: Mechanisms and models. Lancet Neurol 2019;18:1045-57.

10. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866-75.

11. Prüss H, Dalmau J, Harms L, Höltje M, Ahnert-Hilger G, Borowski K, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010;75:1735-9.

12. Casares M, Skinner HJ, Gireesh ED, Wombles C, Schweitzer J, Gwyn PG, et al. Successful intrathecal rituximab administration in refractory nonteratoma anti–N-Methyl-D-aspartate receptor encephalitis: A case report. J Neurosci Nurs 2019;51:194-7.

13. Hallowell S, Tebedge E, Oates M, H and E. Rituximab for treatment of refractory anti-NMDA receptor encephalitis in a pediatric patient. J Pediatr Pharmacol Ther 2017;22:118-23.

14. Yang X-Z, Zhu H-D, Ren H-T, Zhu Y-C, Peng B, Cui L-Y, et al. Utility and safety of intrathecal methotrexate treatment in severe anti-N-methyl-D-aspartate receptor encephalitis: A pilot study. Chin Med J (Engl) 2018;131:156-60.

15. Wang D, Wu Y, Ji Z, Wang S, Xu Y, Huang K, et al. A refractory anti-NMDA receptor encephalitis successfully treated by bilateral salpingo-oophorectomy and intrathecal injection of methotrexate and dexamethasone: A case report. J Int Med Res 2020;48:300060520925666. doi: 10.1177/0300060520925666.

16. Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 2011;76:929-30.

17. Bergman J, Burman J, Gilthorpe JD, Zetterberg H, Jiltsova E, Bergenheim T, et al. Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study. Neurology 2018;91:e1893-901.